Review of topical phage therapy for wounds and burns notes dosing standardization gaps

The growing antimicrobial resistance crisis has led to renewed interest in bacteriophage therapy, mostly for topical uses such as wound/burn care. However, the clinical application of topical phage therapy is delayed due to a major problem that dosing and delivery protocols lack standardization. By gathering scattered published studies on topical phage therapy, this review attempts to bridge the most important gap. We unpack the complicated interactions between phage titer (most of the time 107–109 PFU/mL), multiplicity of infection (MOI), and the stability of various formulations such as hydrogels, creams, and polymer-based sprays, which are some of the factors that determine the effectiveness of the treatment to the greatest extent. Our review extends to the bacterial load and biofilm maturity, whose raising is the main explanation of why mature biofilms need higher, repeated dosing or a combination of antibiotics and depolymerase-armed phages to be treated effectively. Additionally, we collect pharmacokinetic/pharmacodynamic (PK/PD) essentials from animal experiments and talk about the role of wound dressings in the controlled delivery of phages. The authors argue that topical phage therapy can be most effective only when it is a combined effort: accurate dose calculation, intelligent formulation design, and careful planning of the time for application. To get from the laboratory to the clinic, the field needs to urgently implement standardized PK/PD frameworks, stringent stability testing, and comprehensive clinical trials. This paper brings together these components to serve as a practical guide in the development of efficient, dependable, and easily translatable topical phage treatment regimens.